SCHEMBL2910977

SCHEMBL2910977

CCOC(=O)c1cccc(NC(c2ccncc2)c2ccc(F)c(OC)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.48
TP53 P04637 2/20 0.47
CDC25B P30305 1/20 0.46
TSHR P16473 2/20 0.44
MAPK1 P28482 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
BRAF P15056 1/20 0.42
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
JAK1 P23458 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909625 0.90 TP53 (0.47) NAMPTTP53CDC25BTSHRMAPK1
SCHEMBL2909129 0.80 KMT2A (0.45) NAMPTTP53MAPK1HSD17B10NPC1
SCHEMBL2910978 0.71 NAMPT (0.45) NAMPTCDC25BTSHRMAPK1HSD17B10
SCHEMBL22046583 0.70 NPSR1 (0.60) TP53CDC25BTSHRMAPK1HSD17B10
SCHEMBL396078 0.69 NPSR1 (0.62) TP53CDC25BTSHRMAPK1HSD17B10
SCHEMBL3125816 0.69 LMNA (0.48) TSHRNPC1RAB9AKDM4EALDH1A1
SCHEMBL29106420 0.68 CDC25B (0.54) NAMPTCDC25BTSHRMAPK1HSD17B10
SCHEMBL3086665 0.68 F7 (0.48) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL10389937 0.67 MAPT (0.56) TP53CDC25BTSHRMAPK1HSD17B10
SCHEMBL19922649 0.67 MAPT (0.56) TP53CDC25BTSHRMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B NAMPT 953/4885TP53 4759/4885CDC25B 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.